Frontier IP notes the following announcement from The Pirbright Institute that it has entered into a collaboration with the Group’s portfolio company, The Vaccine Group (“TVG” or the “Company”), to revolutionise development of vaccines to combat African swine fever (“ASF”).
ASF is highly contagious and deadly to pigs. The virus has devastating impacts, is spreading rapidly around the world and poses a threat to the UK’s pig and pork export market, which was valued at £623 million in 2022. No safe and effective vaccines yet exist for ASF .
The project, expected to take 18 months, is backed by funding from the UK Department for Environment, Food and Rural Affairs, and the Biotechnology and Biological Sciences Research Council, part of UK Research and Innovation.
Frontier IP holds a 17 per cent. equity stake in TVG.
We are delighted that TVG is entering this collaboration with The Pirbright Institute, a world leader in innovation for preventing and controlling viral diseases in livestock. The partnership represents a strong validation for TVG’s herpesvirus-based vaccine platform technology.
Neil Crabb, Frontier IP Chief Executive Officer
The Pirbright Institute statement begins
Pioneering partnership to improve swine health
The Pirbright Institute is partnering with researchers at The Vaccine Group (TVG) in Plymouth on a new project that sets out to control African swine fever (ASF).
Pirbright researchers are collaborating with TVG to accelerate the development of safe and effective vaccines against the deadly contagious disease.
ASF, prevalent on every continent except South America and Antarctica, poses a significant threat to domestic swine and wild boar populations, including endangered species such as babirusa and pygmy hogs.
Despite movement restrictions, the virus continues to spread rapidly across Europe and around the world, threatening global food security, causing substantial economic losses, and devastating biodiversity and farmer livelihoods. In 2022, the UK’s pig and pork export market was valued at over £623 million, which would likely be lost in the event of an outbreak.
Traditional vaccine methods have proven ineffective, prompting the need for innovative solutions.
With funding from the Department for Environment, Food and Rural Affairs and the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), researchers led by Dr Chris Netherton, head of Pirbright’s African Swine Fever Vaccinology research group, in collaboration with Dr Jeremy Salt (CEO) and Dr Michael Jarvis (CSO) at TVG, aim to revolutionise ASF vaccine development.
We’re excited TVG is joining forces with The Pirbright Institute to tackle one of the most pressing challenges in swine health. Our expertise in vaccine technology, combined with Pirbright’s groundbreaking research in African swine fever, presents a unique opportunity to make a real difference in the fight against this devastating disease. Together, we’re committed to developing innovative solutions that will benefit both animals and communities globally.
The Vaccine Group Chief Executive Dr Jeremy Salt
The project adopts a novel approach, utilising bovine herpesvirus 4 (BoHV-4) as a platform for developing ASF vaccines, leveraging recent advancements in ASF vaccinology and porcine immunology. By harnessing TVG’s expertise in herpesvirus-based vaccine platforms, the team hopes to catalyse the development of safe and effective ASF vaccines.
The data generated by this project on the immune response to ASFV infection will interest researchers studying other swine pathogens like porcine respiratory and reproductive syndrome virus, swine influenza virus, and classical swine fever virus. Through our collaboration with TVG, The Pirbright Institute is not only helping to fight African swine fever, but also revolutionising vaccine development. By harnessing bovine herpesvirus 4, we aim to create safer, more effective vaccines for global pig protection.
Dr Chris Netherton, head of Pirbright’s African swine fever vaccionology research group
The project is expected to take 18 months and will identify a novel vaccine candidate.
